The clinical significance of interferon inducible protein-10 in patients having chronic hepatitis C with genotype I.
- Author:
Young Sun LEE
1
;
Ji Hoon KIM
;
Hyun Jung LEE
;
Eileen L YOON
;
Tae Hyung KIM
;
Jin Sung KOH
;
Sunwon KIM
;
Sang Ah LIM
;
Joon Young LEE
;
Beom Jae LEE
;
Jong Eun YOEN
;
Jong Jae PARK
;
Jae Seon KIM
;
Young Tae BAK
;
Kwan Soo BYUN
Author Information
1. Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. kjhhepar@naver.com
- Publication Type:Original Article
- Keywords:
Chronic hepatitis C;
Pegylated interferon;
Interferon-inducible protein-10;
Virologic response
- MeSH:
Enzyme-Linked Immunosorbent Assay;
Genotype;
Hepatitis C, Chronic;
Hepatitis, Chronic;
Humans;
Interferons;
Retrospective Studies;
Ribavirin;
RNA
- From:Korean Journal of Medicine
2010;79(6):652-660
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Recent studies have shown that serum interferon gamma-inducible protein-10 (IP-10) concentration decreased after pegylated interferon and ribavirin therapy, and was associated with a sustained virologic response (SVR). The aim of this study was to investigate the clinical significance of the pretreatment IP-10 level and change in serum IP-10 level between 1 month before and after treatment and its association with various virologic responses in patients having chronic hepatitis C (CHC) with genotype 1 undergoing pegylated interferon and ribavirin therapy. METHODS: Thirty-six patients having CHC with genotype I undergoing pegylated interferon and ribavirin therapy who had available stored sera 1 month before and after treatment were enrolled retrospectively. Serum IP-10 levels were measured by ELISA. Serum HCV RNA was measured by RT-PCR (detection limit<50 IU/mL). RESULTS: The mean age of patients (n=36; 21 men) was 53.5 years, and the mean of pretreatment HCV RNA levels was 5.7 log10 IU/mL. The serum IP-10 level at 1 month after treatment significantly decreased from 432.2 to 306.5 pg/mL (p=0.033). The rate of rapid virologic response (RVR), early virologic response (EVR), end-of-treatment response (ETR), and SVR were 58%, 83%, 74%, and 57%, respectively. No significant difference in pretreatment IP-10 levels was observed between the patients with (RVR, EVR, ETR, and SVR) and without various virologic responses (p>0.05). The change in serum IP-10 between 1 month before and after treatment had no clinical meaning based on various virologic responses (p>0.05). CONCLUSIONS: The level of pretreatment IP-10 and change in IP-10 level between 1 month before and after treatment were not predictive factors of a SVR. Additional large-scale studies to determine the SVR-predicting role of serum IP-10 levels in patients with CHC are needed.
